In this trial, patients with early-stage HER2-positive BC were divided into two groups undergoing NAC: (1) receiving non-targeted chemotherapy plus HER2-dual blockade with trastuzumab and pertuzumab, and (2) receiving HER2 dual blockade plus endocrine therapy. The gene discussed is ERBB2; the disease is breast cancer.